Elanco Animal Health Incorporated (ELAN)
| Market Cap | 11.47B |
| Revenue (ttm) | 4.59B |
| Net Income (ttm) | 36.00M |
| Shares Out | 496.86M |
| EPS (ttm) | 0.07 |
| PE Ratio | 325.81 |
| Forward PE | 24.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,133,641 |
| Open | 22.64 |
| Previous Close | 22.84 |
| Day's Range | 22.37 - 23.13 |
| 52-Week Range | 8.02 - 23.89 |
| Beta | 1.87 |
| Analysts | Buy |
| Price Target | 23.11 (+0.13%) |
| Earnings Date | Feb 24, 2026 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price target is $23.11, which is an increase of 0.13% from the latest price.
News
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age...
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional A...
Jim Cramer Praises Elanco Animal Health: 'They've Turned That Company Around'
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Elanco Animal Health Incorporated (NYSE: ELAN).
Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript
Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript
Animal Health Focused Elanco Details Pipeline Momentum, US Investments, Cost-Saving Plans
On Tuesday, Elanco Animal Health Incorporated (NYSE: ELAN) used its first Investor Day in five years to signal a turning point for the company, outlining a more focused strategy aimed at sustainable g...
Elanco Investor Day Defines New Era as Sustainable Growth Company
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and lo...
Elanco Animal Health Incorporated (ELAN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Elanco executive appointed as Neurizon's Board Observer
MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advanc...
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Auth...
Elanco Animal Health Stock Is Undervalued: Analyst
As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.
Elanco to Participate in the Upcoming Investor Conferences
INDIANAPOLIS , Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, December 3,...
6 Healthcare Stocks With Strong Upward Momentum
Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of...
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio INDIANAPOLIS , Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio...
Elanco Animal Health CEO: Seeing a willingness to spend, durability even in 'consumer tested' time
Jeff Simmons, Elanco Animal Health CEO, joins 'The Exchange' to discuss what's driving the company's earnings results, where the company's is devoting the most resources and much more.
Elanco Animal Health Incorporated (ELAN) Q3 2025 Earnings Call Transcript
Elanco Animal Health Incorporated ( ELAN) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tiffany Kanaga Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Exec...
Elanco Animal Health Reports Third Quarter 2025 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% org...
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tic...
Elanco gets US FDA emergency nod for dog drug as threat of flesh-eating parasite looms
Elanco Animal Health said on Friday it had received an emergency use authorization from the U.S. Food and Drug Administration for its flea and tick drug to treat dogs infected with a flesh-eating para...
Elanco Animal Health Obtains FDA Authorization for Screwworm Treatment
Health and Human Services Secretary Robert F. Kennedy Jr. determined that New World screwworm presents significant potential for a public health emergency.
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First FDA emergency use authorization (EUA) ever granted f...
Elanco to Host Investor Day on December 9
INDIANAPOLIS , Oct. 16, 2025 /PRNewswire/ -- Elanco Animal Health, Inc. (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9 a.m. to 12 p.m.
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement
GREENFIELD, Ind. , Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025.